Advancing Obesity Science

At Amgen, we are advancing research to better understand the biology of obesity and related conditions. Leveraging 45+ years of cutting-edge science and human genetics, we are currently studying maridebart cafraglutide, or MariTide for short  (formerly AMG 133), for monthly or even less frequent dosing in obesity, atherosclerotic cardiovascular disease, heart failure, obstructive sleep apnea and type 2 diabetes.1-7  Amgen is also developing other potential obesity treatments, including both oral and injectable approaches. This work reflects our commitment to people living with cardiovascular and metabolic diseases. 

MariTide's Mechanism

Amgen’s lead investigational asset in obesity and related conditions is the first-of-its-kind antibody-peptide conjugate designed to leverage GIPR antagonism and GLP-1R agonism, which has the potential for monthly or less frequent dosing. MariTide is being studied for its potential to target key biological pathways involved in obesity and related conditions.

Read More About our Science

The Story of Maridebart Cafraglutide (MariTide)
Decoding the Genetics of Obesity
Mechanism of Action for our Lead Asset Maridebart Cafraglutide (MariTide, AMG 133)

Mechanism of Action for our Lead Asset Maridebart Cafraglutide (MariTide, AMG 133)
Targeting Obesity Using Biology
Inside Amgen’s Phase 3 MARITIME Program: Advancing the Future of Obesity Care

Learn more about our approach to obesity and related conditions.

Learn more

References

  1. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06858878. Accessed April 27, 2026.
  2. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT06987695. Accessed April 27, 2026.
  3. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07037459. Accessed April 27, 2026.  
  4. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07037433. Accessed April 27, 2026.  
  5. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07225686. Accessed April 27, 2026.  
  6. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07226765. Accessed April 27, 2026.  
  7. Fryar CD, Afful J, Saif NT. Prevalence of overweight, obesity, and severe obesity among adults age 20 and over: United States, 1960–1962 through August 2021-August 2023. NCHS Health E-Stat. 2026 Feb;(111):1–7.